Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 2/3 1Phase 1 1

Status

Completed 14Recruiting 6Withdrawn 4Terminated 3Active not recruiting 2Unknown 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Other solid neoplasm 1

Conditions

Cytokine Release Syndrome 2Schwannomatosis 1Pain 1Neurilemmoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Chronic Pain 1Burkitt Lymphoma 1Advanced Malignant Solid Neoplasm 1

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × siltuximab × Clear all
NCT07570173 2026-05-26

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
340 enrolled
Lymphoid

Burkitt Lymphoma

NCT06679829 2026-04-24

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
215 enrolled
Plasma cell

Multiple Myeloma

NCT05684692 2026-04-23

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Massachusetts General Hospital

Phase 2 Recruiting
40 enrolled

Schwannomatosis, Neurilemmoma, Pain, Chronic Pain

NCT06470971 2026-01-20

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
40 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
20 enrolled
Plasma cell

Cytokine Release Syndrome, Neoplasms, Plasma Cell

NCT06447376 2025-05-11

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Case Comprehensive Cancer Center

Phase 1 Recruiting
20 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡